This company has been marked as potentially delisted and may not be actively trading. Neuralstem (CUR) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock CUR vs. BCLI, FRTX, ALBT, KLTO, APTO, CELZ, GENE, TTNP, PALI, and ONVOShould you be buying Neuralstem stock or one of its competitors? The main competitors of Neuralstem include Brainstorm Cell Therapeutics (BCLI), Fresh Tracks Therapeutics (FRTX), Avalon GloboCare (ALBT), Klotho Neurosciences (KLTO), Aptose Biosciences (APTO), Creative Medical Technology (CELZ), Genetic Technologies (GENE), Titan Pharmaceuticals (TTNP), Palisade Bio (PALI), and Organovo (ONVO). These companies are all part of the "medical" sector. Neuralstem vs. Brainstorm Cell Therapeutics Fresh Tracks Therapeutics Avalon GloboCare Klotho Neurosciences Aptose Biosciences Creative Medical Technology Genetic Technologies Titan Pharmaceuticals Palisade Bio Organovo Neuralstem (NASDAQ:CUR) and Brainstorm Cell Therapeutics (NASDAQ:BCLI) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their community ranking, institutional ownership, dividends, media sentiment, valuation, analyst recommendations, profitability, earnings and risk. Does the media favor CUR or BCLI? In the previous week, Brainstorm Cell Therapeutics had 3 more articles in the media than Neuralstem. MarketBeat recorded 3 mentions for Brainstorm Cell Therapeutics and 0 mentions for Neuralstem. Brainstorm Cell Therapeutics' average media sentiment score of 0.93 beat Neuralstem's score of 0.00 indicating that Brainstorm Cell Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Neuralstem Neutral Brainstorm Cell Therapeutics Positive Which has better valuation & earnings, CUR or BCLI? Neuralstem has higher revenue and earnings than Brainstorm Cell Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNeuralstem$260K5.82-$4.93MN/AN/ABrainstorm Cell TherapeuticsN/AN/A-$17.19M-$3.66-0.27 Is CUR or BCLI more profitable? Brainstorm Cell Therapeutics has a net margin of 0.00% compared to Neuralstem's net margin of -39,417.64%. Brainstorm Cell Therapeutics' return on equity of 0.00% beat Neuralstem's return on equity.Company Net Margins Return on Equity Return on Assets Neuralstem-39,417.64% -170.51% -110.16% Brainstorm Cell Therapeutics N/A N/A -528.56% Which has more volatility & risk, CUR or BCLI? Neuralstem has a beta of 1.81, meaning that its share price is 81% more volatile than the S&P 500. Comparatively, Brainstorm Cell Therapeutics has a beta of 0.6, meaning that its share price is 40% less volatile than the S&P 500. Do insiders & institutionals believe in CUR or BCLI? 38.3% of Neuralstem shares are held by institutional investors. Comparatively, 14.3% of Brainstorm Cell Therapeutics shares are held by institutional investors. 5.4% of Neuralstem shares are held by company insiders. Comparatively, 6.7% of Brainstorm Cell Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Does the MarketBeat Community prefer CUR or BCLI? Brainstorm Cell Therapeutics received 13 more outperform votes than Neuralstem when rated by MarketBeat users. However, 66.83% of users gave Neuralstem an outperform vote while only 59.51% of users gave Brainstorm Cell Therapeutics an outperform vote. CompanyUnderperformOutperformNeuralstemOutperform Votes27866.83% Underperform Votes13833.17% Brainstorm Cell TherapeuticsOutperform Votes29159.51% Underperform Votes19840.49% Do analysts prefer CUR or BCLI? Brainstorm Cell Therapeutics has a consensus price target of $30.00, indicating a potential upside of 2,976.92%. Given Brainstorm Cell Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Brainstorm Cell Therapeutics is more favorable than Neuralstem.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Neuralstem 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Brainstorm Cell Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryBrainstorm Cell Therapeutics beats Neuralstem on 9 of the 15 factors compared between the two stocks. Get Neuralstem News Delivered to You Automatically Sign up to receive the latest news and ratings for CUR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CUR vs. The Competition Export to ExcelMetricNeuralstemBiological Products, Except Diagnostic IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.51M$2.92B$5.47B$7.82BDividend YieldN/A1.91%5.43%4.30%P/E RatioN/A29.7522.3718.43Price / Sales5.82481.28391.12101.46Price / CashN/A168.6838.1834.62Price / Book0.113.036.684.19Net Income-$4.93M-$72.17M$3.22B$248.05M Neuralstem Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CURNeuralstemN/A$0.72-2.1%N/A-88.2%$1.51M$260,000.000.006BCLIBrainstorm Cell Therapeutics3.6037 of 5 stars$0.91+5.8%$30.00+3,196.7%-87.8%$5.94MN/A-0.1940Short Interest ↑Positive NewsGap UpFRTXFresh Tracks TherapeuticsN/A$0.94-0.5%N/A+1.6%$5.59M$10.06M-0.6620ALBTAvalon GloboCare1.1958 of 5 stars$3.17-11.3%N/A-10.2%$5.23M$1.31M-0.165Short Interest ↑Gap UpKLTOKlotho NeurosciencesN/A$0.14-9.2%N/AN/A$3.99MN/A0.00N/AGap DownAPTOAptose Biosciences1.6679 of 5 starsN/A$93.00+∞N/A$3.66MN/A-0.5831Gap DownHigh Trading VolumeCELZCreative Medical Technology1.1806 of 5 stars$2.03+2.8%N/A-55.4%$3.54M$11,000.00-0.535Negative NewsGENEGenetic TechnologiesN/A$0.77flatN/AN/A$3.37M$7.66M0.0050News CoverageHigh Trading VolumeTTNPTitan Pharmaceuticals1.4716 of 5 stars$3.43-7.9%N/A-46.9%$3.13M$180,000.00-0.6610Analyst ForecastNews CoveragePALIPalisade Bio3.1672 of 5 stars$0.70-0.6%$23.00+3,167.0%-88.3%$3.10M$250,000.00-0.0510Short Interest ↓Gap DownONVOOrganovo0.3902 of 5 stars$1.71-2.3%N/AN/A$2.91M$122,000.00-2.0120News CoverageGap Down Related Companies and Tools Related Companies BCLI Alternatives FRTX Alternatives ALBT Alternatives KLTO Alternatives APTO Alternatives CELZ Alternatives GENE Alternatives TTNP Alternatives PALI Alternatives ONVO Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CUR) was last updated on 4/26/2025 by MarketBeat.com Staff From Our PartnersTrump’s tariffs just split the AI market in twoTrump’s tariff just split the AI market – among others – in two. One group of AI companies—the ones relying...Traders Agency | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...Crypto Swap Profits | SponsoredTrump’s treachery Forget what the media tells you. Trump’s inner circle may be pushing a financial reset that mirrors moves from...Porter & Company | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredTrump announcement boosts “next Bitcoin”President Trump just made his first big crypto move ... Announcing the creation of a national strategic re...Weiss Ratings | SponsoredHere’s How to Claim Your Stake in Elon’s Private Company, xAII predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neuralstem, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Neuralstem With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
